摘要
目的探讨神经节苷脂GM1治疗帕金森氏病(PD)的疗效和安全性。方法对33例长期服用左旋多巴等治疗帕金森氏病药物后出现症状波动的患者,加用神经节苷脂GM1100mg/d,静脉滴注,每日1次,疗程4周。分别在GM1治疗后2、3、4周对患者进行帕金森病统一评分量表(UPDRS)运动评分及日常生活活动能力(ADL)评分,并观察治疗期间药物的毒副作用。结果33例PD患者在GM1治疗后2、3、4周UPDRS运动评分分别为(23.5±8.9)、(22.8±8.3)和(22.5±9.1),与治疗前(36.7±10.2)比较,均有非常显著性差异(P<0.01);ADL评分分别为(21.4±10.9)、(20.3±9.5)和(20.6±10.2),与治疗前(30.5±12.1)比较,亦均有非常显著性差异(P<0.01)。但治疗2、3、4周的UPDRS运动评分或ADL评分两两比较,无显著性差异(P>0.05)。治疗期间没有观察到明显的毒副作用。结论对长期服用左旋多巴出现症状波动或疗效减退的PD患者,加用GM1治疗,能在一定程度上改善患者的运动功能和日常生活能力。
Objective To evaluate the safety and efficacy of GM1 ganglioside treatment for persons with Parkinson＇s disease. Methods 33 Parkinson＇s disease patients with a fluctuating response to levodopa received 100 mg GM1 ganglioside （used as add-on agent to the previous medication regimen） daily. Unified Parkinson＇s disease Rating scale （UPDRS） motor score and Activities of Daily Living （ADL） score were measure before and 2, 3 or 4 weeks after treatment. The side-effect of GM1 during treatment were observed. Results After 2, 3, 4 weeks of treatment, There was significant improvement in patients with GM1 treament on the UPDRS motor scores were （23.5±8.9）, （22.8±8.3） and （22.5±9.1） respectively, which was improved compared with that before （36.7±10. 2） （P〈0.01）. The ADL portion of the UPDRS at these time were （21.4± 10.9）, （20.3±9.5） and （20.62 10.2） respectively, also showed significant improvement compared with the baseline （30.5± 12.1） （P〈0.01）. However, there was no significant differece between the scores that measured at the time spots 2 weeks after treatment. No side-effect had been observed. Conclusion GM1 ganglioside can improve neurologic function significantly in PD patients with fluctuating response to levodopa.
出处
《中国康复理论与实践》
CSCD
2005年第7期580-581,共2页
Chinese Journal of Rehabilitation Theory and Practice
